ADVANTAGENE, INC — Department of Health and Human Services SBIR Phase I: 102

Description

DESCRIPTION provided by applicant Pancreatic adenocarcinoma has a dismal year survival of andlt The only potential curative treatment is resection but this is achieved in andlt of patients and most still die due to micrometastases or residual disease Patients with unresectable disease receive palliative chemotherapy with a median survival of less than months This application proposes a multi pronged approach with an aggressive chemoradiation regimen combined with a viral immuno oncology product to attack residual and metastatic disease The goal is to increase the resection rate and year survival without further compromising quality of life The project builds on a completed Phase a trial with Gene Mediated Cytotoxic Immunotherapy GMCI combined with chemoradiation and surgery that established a safe dose level and demonstrated immune stimulation in pancreatic cancer GMCI generates a polyvalent anti tumor immune response through local delivery of aglatimagene besadenovec AdV tk plus prodrug and has demonstrated synergy with standard of care SOC in multiple tumor types In preclinical studies the CD T cell dependent systemic effect is potentiated by radiation chemotherapy and surgery which debulk and decrease immune inhibitory factors elicited by tumors GMCI significantly improved survival in a recent Phase study in combination with chemoradiation in malignant glioma patients that had received total resection A neoadjuvant regimen using modified FOLFIRINOX mFX followed by gemcitabine radiation GR was piloted by the investigators at OSU in borderline resectable BRPC and locally advanced pancreatic cancer LAPC The regimen showed equivalent efficacy with less toxicity than standard FOLFIRINOX and led to more patients becoming resectable Components of the regimen have been shown to suppress immune inhibitory factors elicited by tumors including myeloid derived suppressor cells MDSC regulatory T cells Treg and inhibitory cytokines These data support the rationale for combining GMCI with mFX GR surgical resection This Fast Track application proposes a Ph b clinical trial in BRPC and LAPC The clinical protocol has received all the necessary regulatory approvals and is ready to launch The protocol includes a single arm Phase Ib stage to establish the feasibility of the treatment plan Phase I segment of the Fast track grant followed by a randomized Phase stage of the trial Phase II grant segment Immune biomarkers including effector T cells Tregs MDSCs and cytokines will be measured before and after each treatment phase and compared between the control and test arm to better understand the mFX GR and GMCI immune effects in this patient population This will be the first study of an immunotherapy combined with mFX GR and the first randomized clinical study of GMCI for PanCa The goal is to obtain the necessary data to support a decision for or against a definitive efficacy study that may improve the outcomes for patients with this devastating disease The transition from Phase Ib to Phase II is preplanned in the protocol as a measurable milestone and will benefit from continuity thus the Fast Track submission PUBLIC HEALTH RELEVANCE Pancreatic adenocarcinoma has a year survival rate of less than the lowest of all major cancers with more than deaths in the US each year Pancreatic cancer is a major focus of the Recalcitrant Cancer Research Act recently passed to encourage research support for this deadly cancer This application proposes a multi pronged approach with an aggressive chemoradiation regimen combined with a viral immuno oncology product for pancreatic cancer The goal is to increase the resection rate and year survival without further compromising quality of life The project builds on a completed Phase a trial with Gene Mediated Cytotoxic Immunotherapy GMCI combined with chemoradiation and surgery that established a safe dose level and demonstrated immune stimulation in pancreatic cancer This Fast Track grant proposal seeks to build on these results with a follow on Phase b clinical trial Our clinical objective is to increase the number of patients that may undergo potentially curative resections and prevent development of metastases thus potentially achieve long term clinical benefit Our commercial goal is to develop a new therapeutic product for pancreatic cancer